Fig. 3: CXCL13 expression in the lymph node demonstrates a difference between iMCD-TAFRO and reactive but not iMCD-NOS and reactive.
From: CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Representative germinal centers from a iMCD-TAFRO, b iMCD-NOS, c RA, and d reactive lymph nodes, bars represent 200 µm. e Comparison of positive pixel intensity in iMCD (n = 17) with reactive (n = 17; p = 0.07) and RA (n = 9; p = 0.45). The error bar represents the standard error of the mean. f Comparison of the number of germinal centers in iMCD (n = 17), RA (n = 9), and reactive (n = 17) lymph nodes. iMCD lymph nodes have significantly more germinal centers than RA (p = 0.002) but not reactive (p = 0.596). g Comparison of positive pixel intensity between iMCD-TAFRO (n = 9) and reactive (n = 17) and between iMCD-NOS (n = 8) and reactive. iMCD-TAFRO demonstrates significantly more CXCL13 expression than reactive (p = 0.003), but there is no difference between iMCD-NOS and reactive (p = 0.67). The error bar represents the standard error of the mean. Statistical differences were determined by a two-tailed non-parametric normal scores test. Box plots include a center line (median), box limits (upper and lower quartiles), whiskers (1.5x interquartile range), and all data points. Source data are provided as a Source Data file.
